Literature DB >> 17360497

Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior.

Ilse Gantois1, Ke Fang, Luning Jiang, Daniela Babovic, Andrew J Lawrence, Vincenzo Ferreri, Yaroslav Teper, Bianca Jupp, Jenna Ziebell, Cristina M Morganti-Kossmann, Terence J O'Brien, Rachel Nally, Günter Schütz, John Waddington, Gary F Egan, John Drago.   

Abstract

Huntington's disease is characterized by death of striatal projection neurons. We used a Cre/Lox transgenic approach to generate an animal model in which D1 dopamine receptor (Drd1a)+ cells are progressively ablated in the postnatal brain. Striatal Drd1a, substance P, and dynorphin expression is progressively lost, whereas D2 dopamine receptor (Drd2) and enkephalin expression is up-regulated. Magnetic resonance spectroscopic analysis demonstrated early elevation of the striatal choline/creatine ratio, a finding associated with extensive reactive striatal astrogliosis. Sequential MRI demonstrated a progressive reduction in striatal volume and secondary ventricular enlargement confirmed to be due to loss of striatal cells. Mutant mice had normal gait and rotarod performance but displayed hindlimb dystonia, locomotor hyperactivity, and handling-induced electrographically verified spontaneous seizures. Ethological assessment identified an increase in rearing and impairments in the oral behaviors of sifting and chewing. In line with the limbic seizure profile, cell loss, astrogliosis, microgliosis, and down-regulated dynorphin expression were seen in the hippocampal dentate gyrus. This study specifically implicates Drd1a+ cell loss with tail suspension hindlimb dystonia, hyperactivity, and abnormal oral function. The latter may relate to the speech and swallowing disturbances and the classic sign of tongue-protrusion motor impersistence observed in Huntington's disease. In addition, the findings of this study support the notion that Drd1a and Drd2 are segregated on striatal projection neurons.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360497      PMCID: PMC1820729          DOI: 10.1073/pnas.0611625104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.

Authors:  Nicola Pavese; Thomasin C Andrews; David J Brooks; Aileen K Ho; Anne E Rosser; Roger A Barker; Trevor W Robbins; Barbara J Sahakian; Stephen B Dunnett; Paola Piccini
Journal:  Brain       Date:  2003-05       Impact factor: 13.501

Review 2.  Chorea and related disorders.

Authors:  R Bhidayasiri; D D Truong
Journal:  Postgrad Med J       Date:  2004-09       Impact factor: 2.401

3.  Dopamine modulates cell cycle in the lateral ganglionic eminence.

Authors:  Nobuyo Ohtani; Tomohide Goto; Christian Waeber; Pradeep G Bhide
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

4.  Electroencephalographic characterisation of pentylenetetrazole-induced seizures in mice lacking the alpha 4 subunit of the neuronal nicotinic receptor.

Authors:  C D McColl; M K Horne; D I Finkelstein; J Y F Wong; S F Berkovic; J Drago
Journal:  Neuropharmacology       Date:  2003-02       Impact factor: 5.250

5.  Altered striatal function in a mutant mouse lacking D1A dopamine receptors.

Authors:  J Drago; C R Gerfen; J E Lachowicz; H Steiner; T R Hollon; P E Love; G T Ooi; A Grinberg; E J Lee; S P Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

6.  Directed migration of neuronal precursors into the ischemic cerebral cortex and striatum.

Authors:  Kunlin Jin; Yunjuan Sun; Lin Xie; Alyson Peel; Xiao Ou Mao; Sophie Batteur; David A Greenberg
Journal:  Mol Cell Neurosci       Date:  2003-09       Impact factor: 4.314

7.  Topographical Assessment of Ethological and Dopamine Receptor Agonist-Induced Behavioral Phenotype in Mutants with Congenic DARPP-32 'Knockout'.

Authors:  Rachel E Nally; Fergal N McNamara; Jeremiah J Clifford; A Kinsella; Orna Tighe; David T Croke; Allen A Fienberg; Paul Greengard; John L Waddington
Journal:  Neuropsychopharmacology       Date:  2003-12       Impact factor: 7.853

Review 8.  Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect.

Authors:  Michael S Levine; Carlos Cepeda; Miriam A Hickey; Sheila M Fleming; Marie-Françoise Chesselet
Journal:  Trends Neurosci       Date:  2004-11       Impact factor: 13.837

9.  Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.

Authors:  A S Tattersfield; R J Croon; Y W Liu; A P Kells; R L M Faull; B Connor
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

10.  Glial responses associated with dopaminergic striatal reinnervation following lesions of the rat substantia nigra.

Authors:  Davor Stanic; Wanida Tripanichkul; John Drago; David I Finkelstein; Malcolm K Horne
Journal:  Brain Res       Date:  2004-10-08       Impact factor: 3.252

View more
  29 in total

1.  Differential regulation of motor control and response to dopaminergic drugs by D1R and D2R neurons in distinct dorsal striatum subregions.

Authors:  Pierre F Durieux; Serge N Schiffmann; Alban de Kerchove d'Exaerde
Journal:  EMBO J       Date:  2011-11-08       Impact factor: 11.598

2.  A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.

Authors:  Hyo Jin Son; Ji Ae Lee; Nari Shin; Ji Hyun Choi; Jai Woong Seo; Dae Yoon Chi; Cheol Soon Lee; Eun-Mee Kim; Han Choe; Onyou Hwang
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  In Vivo Evaluation of the Mechanical and Viscoelastic Properties of the Rat Tongue.

Authors:  Emanuele Loro; Stephen H Wang; Richard J Schwab; Tejvir S Khurana
Journal:  J Vis Exp       Date:  2017-07-06       Impact factor: 1.355

4.  Synergistic roles for G-protein γ3 and γ7 subtypes in seizure susceptibility as revealed in double knock-out mice.

Authors:  William F Schwindinger; Uyenlinh L Mirshahi; Kelly A Baylor; Kathleen M Sheridan; Anna M Stauffer; Stephanie Usefof; Mark M Stecker; Tooraj Mirshahi; Janet D Robishaw
Journal:  J Biol Chem       Date:  2011-12-29       Impact factor: 5.157

Review 5.  Investigating striatal function through cell-type-specific manipulations.

Authors:  A C Kreitzer; J D Berke
Journal:  Neuroscience       Date:  2011-08-12       Impact factor: 3.590

6.  Decreased dopamine receptor 1 activity and impaired motor-skill transfer in Dyt1 ΔGAG heterozygous knock-in mice.

Authors:  Fumiaki Yokoi; Mai T Dang; Jun Liu; Jason R Gandre; Kelly Kwon; Robert Yuen; Yuqing Li
Journal:  Behav Brain Res       Date:  2014-11-29       Impact factor: 3.332

7.  The PtdIns(3,4)P(2) phosphatase INPP4A is a suppressor of excitotoxic neuronal death.

Authors:  Junko Sasaki; Satoshi Kofuji; Reietsu Itoh; Toshihiko Momiyama; Kiyohiko Takayama; Haruka Murakami; Shinsuke Chida; Yuko Tsuya; Shunsuke Takasuga; Satoshi Eguchi; Ken Asanuma; Yasuo Horie; Kouichi Miura; Elizabeth Michele Davies; Christina Mitchell; Masakazu Yamazaki; Hirokazu Hirai; Tadaomi Takenawa; Akira Suzuki; Takehiko Sasaki
Journal:  Nature       Date:  2010-05-12       Impact factor: 49.962

8.  Effects of dopamine D1 and D2 receptor antagonists on laryngeal neurophysiology in the rat.

Authors:  Xin Feng; Victor M Henriquez; Judith R Walters; Christy L Ludlow
Journal:  J Neurophysiol       Date:  2009-06-17       Impact factor: 2.714

9.  In hamsters the D1 receptor antagonist SCH23390 depresses ventilation during hypoxia.

Authors:  Evelyn H Schlenker
Journal:  Brain Res       Date:  2007-11-01       Impact factor: 3.252

10.  Inactivation of ceramide synthase 6 in mice results in an altered sphingolipid metabolism and behavioral abnormalities.

Authors:  Philipp Ebel; Katharina Vom Dorp; Elisabeth Petrasch-Parwez; Armin Zlomuzica; Kiyoka Kinugawa; Jean Mariani; David Minich; Christina Ginkel; Jochen Welcker; Joachim Degen; Matthias Eckhardt; Ekrem Dere; Peter Dörmann; Klaus Willecke
Journal:  J Biol Chem       Date:  2013-06-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.